Ascelia Pharma AB (ACE) AI Stock Analysis

• Market Cap: kr396.46M
• Dividend Yield: N/A
• Average Volume (3M): 1.75M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.82
• Revenue Growth: N/A
• EPS Growth: 31.62%
• Country: SE
• Employees: 11
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.13
• Shares Outstanding: 126,868,800
• 10 Day Avg. Volume: 1,883,755
• 30 Day Avg. Volume: 1,753,338
• PEG Ratio: 0.04
• Price to Book (P/B): 2.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.51
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: kr3.00 ▼(-5.36% Downside)

The score is primarily weighed down by weak financial performance (no revenue, sizable losses, and ongoing cash burn despite low leverage). Technicals provide modest support from improving short-term momentum, but longer-term trend remains below key moving averages. Valuation signals are limited and unattractive due to negative earnings and no dividend.

Positive Factors

Regulatory Progress

The FDA's acceptance of Orviglance's NDA is a crucial step towards commercialization, potentially unlocking a significant market opportunity and enhancing long-term revenue prospects.

Patent Protection

The new patent for Orviglance extends market protection, potentially increasing its commercial value and strengthening Ascelia Pharma's competitive position in the market.

Leadership Strengthening

Enhancing the leadership team with experienced professionals supports operational capabilities and aligns with strategic priorities, potentially driving future growth and execution.

Negative Factors

Cash Flow Weakness

Persistent negative cash flow indicates ongoing financial strain, requiring external funding and posing risks to long-term financial stability until revenue generation begins.

Equity Decline

The significant decline in equity reflects ongoing losses and dilution risk, highlighting financial challenges that may impact the company's ability to sustain operations without additional funding.

No Revenue Generation

The absence of revenue generation underscores the company's reliance on external funding and the uncertainty surrounding its path to profitability, posing a challenge to long-term sustainability.

Ascelia Pharma AB Business Overview & Revenue Model

Company Description

Ascelia Pharma AB (publ), a biotech company, operates as an oncology-focused orphan drug development company in Sweden. It is developing Mangoral, a novel non-gadolinium contrast agent, which is in Phase 3 for use in MRI-scans of the liver; and Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 for the treatment of gastric cancer. It has a clinical collaboration agreement with Taiho Oncology, Inc. for the development of Oncoral in combination with LONSURF. Ascelia Pharma AB (publ) was founded in 2000 and is headquartered in Malmö, Sweden.

How the Company Makes Money

Ascelia Pharma AB generates revenue primarily through the research and development of its proprietary drug candidates. The company aims to monetize its products by progressing them through clinical trials and eventually bringing them to the market upon regulatory approval. Key revenue streams include potential licensing agreements, partnerships with larger pharmaceutical companies, and eventual sales of approved products. Additionally, Ascelia may receive milestone payments and royalties from collaborations with other entities in the pharmaceutical industry. The company's success in securing partnerships and advancing its drug candidates through the development pipeline is crucial to its financial performance.

Ascelia Pharma AB Financial Statement Overview

Summary

Ascelia Pharma AB exhibits a challenging financial position typical of early-stage biotech companies. The absence of revenue and persistent net losses, combined with a reliance on external financing, underscore the financial risks associated with the company's operations. However, a strong cash position offers some buffer against immediate liquidity concerns, though long-term sustainability hinges on successful product development and commercialization.

Income Statement

Ascelia Pharma AB has struggled to generate revenue over the past several years, with total revenue consistently at zero. Despite efforts to control costs, the company has reported significant net losses each year, indicative of its heavy R&D expenditure typical within the biotechnology industry. The absence of revenue and consistent negative net income results in extremely poor margins, reflecting a challenging financial position.

Balance Sheet

The balance sheet shows a moderately healthy equity position with a strong level of cash and cash equivalents. However, the company's debt-to-equity ratio has increased over time, reflecting a growing reliance on debt financing. The equity ratio remains stable but has slightly declined, indicating a gradual erosion of equity relative to assets.

Cash Flow

The company's operating cash flow is persistently negative, indicating significant cash burn which is common for biotech firms in development stages. Despite this, recent financing activities have provided substantial cash inflows, helping to offset the negative free cash flow. However, sustainable cash flow from operations remains a critical challenge.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	-938.00K	-1.05M	-3.89M	-8.72M	-825.00K
EBITDA	-77.13M	-67.69M	-108.56M	-132.06M	-128.42M	-98.91M
Net Income	-88.72M	-80.03M	-109.29M	-131.22M	-125.90M	-98.70M
Balance Sheet
Total Assets	136.41M	140.92M	87.07M	218.57M	333.49M	255.37M
Cash, Cash Equivalents and Short-Term Investments	72.28M	75.26M	21.86M	149.56M	261.60M	184.69M
Total Debt	1.18M	25.40M	1.06M	484.00K	1.66M	1.78M
Total Liabilities	22.01M	61.98M	12.74M	37.71M	25.66M	19.32M
Stockholders Equity	114.40M	78.94M	74.33M	180.86M	307.83M	236.06M
Cash Flow
Free Cash Flow	-52.50M	-62.84M	-126.79M	-125.33M	-116.60M	-85.92M
Operating Cash Flow	-52.45M	-62.84M	-126.79M	-125.26M	-116.56M	-85.53M
Investing Cash Flow	-57.00K	0.00	46.00K	-65.00K	-38.00K	75.99M
Financing Cash Flow	46.86M	115.19M	-936.00K	-1.10K	184.87M	92.72M

Ascelia Pharma AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.17
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACE, the sentiment is Negative. The current price of 3.17 is above the 20-day moving average (MA) of 3.09, above the 50-day MA of 2.99, and below the 200-day MA of 3.69, indicating a neutral trend. The MACD of 0.07 indicates Negative momentum. The RSI at 52.85 is Neutral, neither overbought nor oversold. The STOCH value of 53.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ACE.

Ascelia Pharma AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CANTA	67 Neutral	kr1.24B	9.82	81.19%	―	―	―
XBRANE	53 Neutral	kr249.94M	1.35	-16.90%	―	4.64%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ACE	47 Neutral	kr396.46M	-3.64	-79.60%	―	―	31.62%
IMMU	46 Neutral	kr346.23M	-2.83	-16.51%	―	―	31.37%
ISOFOL	44 Neutral	kr201.69M	-2.50	-51.35%	―	―	-34.02%
GUARD	42 Neutral	kr32.17M	-0.21	-199.25%	―	―	0.30%

Ascelia Pharma AB Corporate Events

Ascelia Pharma Appoints Nomination Committee Ahead of 2026 AGM

Ascelia Pharma has appointed its Nomination Committee for the Annual General Meeting to be held in Malmö on 4 May 2026, in line with its governance rules that require representatives from the three largest shareholders together with the chairman of the board. The committee, chaired by Oscar Ahlgren of Salenia and including representatives from major shareholders as well as board chairman Peter Benson, will prepare proposals on board composition, remuneration, auditor selection and principles for future nomination processes, and has invited shareholders to submit proposals by 15 March 2026, underscoring ongoing shareholder engagement and adherence to Swedish corporate governance standards.

Ascelia Pharma Adjusts Share Structure Following Share Saving Program

Ascelia Pharma AB announced a change in its share structure due to the conversion of 53,335 series C shares into ordinary shares as part of a performance-based share saving program. This adjustment results in a total of 127,902,580 shares, impacting the company’s voting structure and reflecting its ongoing commitment to aligning stakeholder interests.

Ascelia Pharma Converts Series C Shares to Ordinary Shares for Incentive Program

Ascelia Pharma’s Board of Directors has decided to convert 53,335 series C shares into ordinary shares to fulfill obligations under a performance-based share saving program. This conversion is part of the company’s long-term incentive program, with shares allocated to the CEO and other participants, maintaining the total number of outstanding shares at 127,902,580. This move reflects Ascelia Pharma’s commitment to incentivizing key personnel, potentially enhancing its strategic positioning in the biotech industry.

FDA Accepts Ascelia Pharma’s Orviglance NDA for Review

Ascelia Pharma announced that the FDA has accepted the New Drug Application for Orviglance, a novel oral contrast agent for liver MRI in patients with impaired kidney function, for review. This milestone is significant as it progresses Orviglance towards availability for patients, potentially impacting the company’s discussions with commercialization partners and addressing a global market need of USD 800 million annually.

Ascelia Pharma Files Patent for Orviglance, Enhancing Market Protection

Ascelia Pharma has filed a new patent application for Orviglance, an innovative liver imaging drug designed to enhance the detection of liver lesions in patients with reduced kidney function. This patent aims to extend market protection for Orviglance until 2046, potentially boosting its commercial value and strengthening Ascelia Pharma’s position in the market.

Ascelia Pharma Advances Orviglance with FDA Submission and Financial Strengthening

Ascelia Pharma AB has submitted a New Drug Application (NDA) for Orviglance to the FDA, marking a significant milestone in its development. The submission follows successful clinical trials demonstrating Orviglance’s efficacy and safety, particularly in improving liver lesion visualization in patients with impaired kidney function. The company has also strengthened its financial position with a SEK 30 million share issue and convertible conversion, extending its cash runway into Q4 2026, beyond the expected FDA approval date. This progress supports Ascelia Pharma’s market potential and ongoing partnership discussions for Orviglance’s commercialization.

Ascelia Pharma Strengthens Leadership Team for Future Growth

Ascelia Pharma AB has announced significant changes to its executive leadership team to enhance its operational capabilities and support future growth. Anton Hansson has been appointed as the new Chief Financial Officer, joining from KPMG, while Jennie Wilborgsson has been promoted to Chief Operating Officer. These changes aim to streamline the management structure and align with the company’s strategic priorities as it focuses on advancing its drug candidates, particularly Orviglance.